CB-103 for Leukemia

Phase-Based Progress Estimates
MD Anderson Cancer Center, Houston, TX
Leukemia+2 More
CB-103 - Drug
< 65
All Sexes
What conditions do you have?

Study Summary

To learn if the combination of 2 study drugs, CB-103 and venetoclax, can help to control T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LBL) in adolescent and young adult patients

Eligible Conditions

  • Leukemia
  • leukemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Leukemia

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: through completion of study or average of 1 year

Year 1
The efficacy of CB-103 in combination with venetoclax will be determined by studying the overall response rate (ORR) of the participants
The safety and tolerability of CB-103 in combination with Venetoclax in adolescent and young adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) .

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Leukemia

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: CB-103 · No Placebo Group · Phase 2

CB-103+VenetoclaxExperimental Group · 2 Interventions: CB-103, Venetoclax · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through completion of study or average of 1 year
Closest Location: MD Anderson Cancer Center · Houston, TX
Photo of MD Anderson Cancer Center 1Photo of MD Anderson Cancer Center 2Photo of MD Anderson Cancer Center 3
2004First Recorded Clinical Trial
153 TrialsResearching Leukemia
521 CompletedClinical Trials

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,772 Previous Clinical Trials
1,795,182 Total Patients Enrolled
437 Trials studying Leukemia
32,245 Patients Enrolled for Leukemia
Branko Cuglievan, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
70 Total Patients Enrolled

Eligibility Criteria

Age < 65 · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Patients with asymptomatic CNS disease are eligible.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.